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DOI 10.1016/j.ccr.2009.12.046Open access under CC BY-NC-ND license.SUMMARYSynthetic sickness/lethality (SSL) can be exploited to develop therapeutic strategies for cancer. Deficiencies
in the tumor suppressor proteinsMLH1 andMSH2 have been implicated in cancer. Here we demonstrate that
deficiency in MSH2 is SSL with inhibition of the DNA polymerase POLB, whereas deficiency in MLH1 is SSL
with DNA polymerase POLG inhibition. Both SSLs led to the accumulation of 8-oxoG oxidative DNA lesions.
MSH2/POLB SSL caused nuclear 8-oxoG accumulation, whereas MLH1/POLG SSL led to a rise in mitochon-
drial 8-oxoG levels. Both SSLs were rescued by silencing the adenine glycosylase MUTYH, suggesting that
lethality could be caused by the formation of lethal DNA breaks upon 8-oxoG accumulation. These data
suggest targeted, mechanism-based therapeutic approaches.INTRODUCTION
One of the recurrent themes of modern cancer drug discovery
has been the design of therapeutic approaches that exploit the
underlying genetic makeup of tumor cells. For example, the effi-
cacy of imatinib (Gleevec) in the treatment of leukemias carrying
the BCR-ABL fusion (Druker et al., 2001) provides a clear
demonstration of how a tumor-specific genetic change may be
exploited clinically. Although targeting gain-of-function onco-
genic events such as the BCR-ABL fusion is conceptually
straightforward, it is not obvious how to pharmacologically tar-
get a tumor suppressor protein that is dysfunctional or even
completely absent. To address this issue, the exploitation of syn-
thetic sickness/lethality (SSL) relationships has been proposed
(Hartwell et al., 1997; Kaelin, 2005). A synthetic lethal relationship
between two genes or proteins exists when loss of function of
either alone is compatible with viability but simultaneous loss
of both causes death (Kaelin, 2005). This concept has beenSignificance
A range of tumor types, including colorectal cancers and in par
ized by loss of eitherMLH1 orMSH2 tumor suppressor gene fu
tumor cells from normal cells. Here we exploit these differences
combined with either MLH1 or MSH2 loss, can lead to tum
approaches to the treatment of MSH2- or MLH1-deficient canextended to the idea of synthetic sickness, where simultaneous
mutation/loss of function of two genes impairs cellular fitness
more than mutation of either gene alone (Kaelin, 2005). These
concepts can be used to design therapeutic approaches that
target the cancer cell-specific loss of tumor suppressor proteins
(Luo et al., 2009). For example, if a tumor suppressor gene and
a second gene are synthetically lethal or sick, inhibition of the
second gene could selectively kill or impair the fitness of tumor
cells.
SSL between DNA repair proteins and pathways has the
potential to be exploited clinically. For example, inhibition of
the base excision repair (BER) pathway protein PARP1 is SSL
with deficiency of either the BRCA1 or BRCA2 tumor sup-
pressor/DNA repair proteins (Bryant et al., 2005; Farmer et al.,
2005; Fong et al., 2009). Similarly, Hartwell and colleagues (Hart-
well et al., 1997) highlighted the potential for exploiting SSL
interactions between mismatch repair (MMR) proteins and
DNA polymerases, a hypothesis based primarily on studies inticular hereditary nonpolyposis colon cancer, are character-
nction. Where this occurs,MLH1 orMSH2 loss distinguishes
to show that inhibition of particular DNA polymerases, when
or cell death. These results suggest targeted therapeutic
cers.
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Figure 1. MSH2 and MLH1 Deficiencies Are Synthetically Sick/Lethal with Silencing of DNA Polymerases
(A) Cell lysates from HCT116 and HCT116+Chr3 cells were analyzed by western blotting using MLH1- and b-tubulin-specific antibodies.
(B) Cell lysates from HEC59 and HEC59+Chr2 cells were analyzed by western blotting using MSH2- and b-tubulin-specific antibodies.
(C) HCT116 (MLH1-deficient) and HCT116+Chr3 (MLH1-proficient) cells were transfected with siRNAs targeting DNA polymerases, and cell viability was
estimated 5 days later using CellTiter-Glo reagent.
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pol3-01 (the ortholog of the human POLD catalytic subunit) are
SSL with loss of the orthologs of the MMR genes EXOI, MSH6,
MSH2, MLH1, and PMS1 (Morrison et al., 1993; Argueso et al.,
2002; Tran et al., 1997). Similarly, the yeast Msh6-PolH double
mutant is not viable (Pavlov et al., 2001) and Msh2-pol2-4
(PolE) mutants are synthetically sick (Tran et al., 1997).
Germline mutations in the MMR genesMLH1 orMSH2 predis-
pose to hereditary nonpolyposis colorectal cancer (HNPCC)/
Lynch syndrome, which accounts for approximately 5% of all
colorectal cancer cases (Jacob and Praz, 2002). Furthermore,
aberrant MLH1 promoter methylation has been proposed as
a cause of some sporadic colorectal cancers (Arnold et al.,
2003; Bettstetter et al., 2007; Peltomaki and Vasen, 2004).
Here, MSH2 and MLH1 are proposed to act as classical tumor
suppressor genes, where tumor cells lose MSH2 or MLH1 func-
tion whereas normal cells retain at least one functional allele.
Although other functions have been ascribed to both MSH2
and MLH1, their most well defined function is in DNA MMR
(Jiricny, 2006). MMR is primarily concerned with repair of DNA
lesions that occur during DNA replication, such as DNA poly-
merase errors that include base-base or insertion/deletion
mismatches. Recent evidence suggests that MMR proteins are
also involved in the repair of DNA lesions caused by oxidative
damage (Colussi et al., 2002; Macpherson et al., 2005). In brief,
DNA mismatches are recognized by the MutSa complex, an
MSH2/MSH6 heterodimer. This interaction enables MutSa to
recruit the MutLa complex, itself a heterodimer consisting of
the MLH1 and PMS2 proteins. MutLa binding stabilizes the Mut-
Sa:DNA interaction and acts as an interface between mismatch
recognition by MutSa and additional proteins that excise and
repair the DNA mismatch (Jiricny, 2006).
Reactive oxygen species, generated by sources such as the
normal metabolic processes of cells as well as environmental
agents, are genotoxic, producing DNA base lesions such as
8-oxoguanine (8-oxoG) (Kamiya, 2003). At replication, 8-oxoG
residues can direct the incorporation of either C or A bases,
which if left unrepaired can be mutagenic, primarily by causing
GC/TA transversions. Mammalian cells have a number of
mechanisms for dealing with 8-oxoG lesions, including BER
and also processes involving MLH1 and MSH2. Repair of
8-oxoG lesions by BER is initiated by removal of the oxidized
base by the DNA glycosylase OGG1. The apurinic (AP) site that
results is further processed by the endonuclease APE1. APE1
hydrolyzes the 50 phosphodiester bond of the sugar backbone
at the AP site, giving rise to a single-strand DNA break (SSB)
flanked by 30 hydroxyl and 50 deoxyribose-5-phosphate (50dRp)
termini. 50dRp termini are then processed via the lyase activity
of DNA polymerase b (POLB). POLB also incorporates the
correct base at the SSB, after which the final break in the DNA
sugar backbone is sealed by DNA ligase III to complete the repair(D) HEC59 and HEC59+Chr2 cells were transfected with siRNAs targeting DNA
reagent.
(E) HEC59 cells were transfectedwith siRNA, and cell lysates were analyzed bywe
shown.
(F) HCT116 cells were transfected with siRNA, and cell lysates were analyzed by w
(G) HEC59 and HEC59+Chr2 cells were transfected with either control siRNA or
(H) HCT116 and HCT116+Chr3 cells were transfected with either control siRNA
Error bars for each individual experiment represent standard errors of the mean.process (Klungland and Bjelland, 2007). The direct involvement
of POLB in this pathway is indicated by the inability of lysates
from Polb/ cells to repair synthetic 8-oxoG lesions (Horton
et al., 2002). DNA polymerase g (POLG) has been implicated
in the repair of 8-oxoG lesions in mitochondria (Lewis et al.,
2007), and like POLB, POLG also possesses a lyase activity
that allows the removal of 50dRp termini. Both MLH1 and
MSH2 have also been implicated in 8-oxoG repair, and defi-
ciency in either gene causes an accumulation of 8-oxoG lesions
(Colussi et al., 2002; Macpherson et al., 2005).
During replication, if adenine is inserted opposite 8-oxoG, the
enzyme MUTYH excises the adenine opposite 8-oxoG, causing
the formation of an abasic site (Oka et al., 2008). This activity is
thought to limit the number of GC/TA transversions that are
otherwise caused by persistent 8-oxoG lesions. Further pro-
cessing of the abasic sites by AP endonuclease results in the
formation of SSBs (Oka et al., 2008). Accumulation of these
SSBs can present a significant threat to the integrity of the
genome and the viability of cells. For example, SSBs can stall
replication forks and cause the formation of potentially lethal
double-strand DNA breaks (DSBs) (Saffhill and Ockey, 1985).
It has also been shown that cell death caused by an accumula-
tion of 8-oxoG lesions is dependent upon MUTYH activity and
characterized by an increase in SSB formation (Oka et al., 2008).
Given the demonstration of SSL relationships involving MLH1
and MSH2 orthologs and DNA polymerases in lower organisms,
we investigated whether similar SSL relationships existed in
human tumor cells and explored their therapeutic potential.
RESULTS
Synthetic Sickness/Lethality Relationships
between DNA Polymerases and MMR Genes
To assess SSL interactions in human cells, we used isogenic
models of MLH1 or MSH2 deficiency. To model MLH1 defi-
ciency, we used the previously characterized human colon
adenocarcinoma cancer cell line HCT116, which carries a homo-
zygous mutation of the MLH1 gene (Umar et al., 1997), and its
MLH1-proficient derivative HCT116+Chr3 cell line, which carries
an extra human chromosome 3 expressing a functional MLH1
allele (Koi et al., 1994) (Figure 1A). To model MSH2 deficiency,
we used the previously characterized human endometrial cell
line HEC59, which harbors compound heterozygous MSH2
nonsensemutations (Boyer et al., 1995), and its MSH2-proficient
derivative HEC59+Chr2 cell line, which carries an extra human
chromosome 2 expressing a functional MSH2 allele (Umar
et al., 1997) (Figure 1B). We screened each of these four cell lines
with a panel of short interfering RNAs (siRNAs) targeting five DNA
polymerases (POL 3, b, h, i, and g: two siRNAs per gene; Eche-
verri et al., 2006) and measured the effect of each siRNA on cell
viability. Most strikingly, targeting of POLG was selective forpolymerases, and cell viability was estimated 5 days later using CellTiter-Glo
stern blotting 72 hr later. POLB- and b-tubulin-specific antibodieswere used as
estern blotting 72 hr later. POLG and b-tubulin antibodies were used as shown.
siRNA targeting POLB, and clonogenic assays were performed.
or siRNA targeting POLG, and clonogenic assays were performed.
See also Figure S1.
Cancer Cell 17, 235–248, March 16, 2010 ª2010 Elsevier Inc. 237
Cancer Cell
Targeting MSH2 or MLH1 Deficiency
238 Cancer Cell 17, 235–248, March 16, 2010 ª2010 Elsevier Inc.
Cancer Cell
Targeting MSH2 or MLH1 DeficiencyMLH1deficiency (Figures 1C and 1F; see Tables S1 andS2 avail-
able online) andMSH2 selectivity could be achieved by targeting
POLB (Figures 1D and 1E; Tables S1 and S2). To more accu-
rately assess the scale of these effects, we used longer-term
clonogenic assays, similar to those used to assess SSL between
PARP1 silencing and loss of BRCA1 or BRCA2 function (Farmer
et al., 2005). In clonogenic assays, the scale of the MSH2/POLB
and MLH1/POLG effects were similar to that observed using
RNA interference-mediated silencing of PARP1 in BRCA1- or
BRCA2-deficient cells (Farmer et al., 2005) (Figures 1G and
1H). To assess the generality of these observations, we used
additional isogenic cell models. POLG silencing was also selec-
tive in A2780cp70 cells, where MLH1 deficiency occurs by
epigenetic silencing of the MLH1 gene (Strathdee et al., 1999)
(Figure S1A; Table S2), as well as in HeLa andMCF7 cells, where
MLH1 and POLG were silenced by using combinations of
siRNAs (Figure S1B). Similarly, the MSH2/POLB SSL was
observed in HeLa cells with stable silencing of MSH2 deficiency
(Figure S1C; Table S2) as well as in HeLa and MCF7 cells trans-
fected with siRNA combinations (Figure S1D). BothMSH2/POLB
and MLH1/POLG SSLs were also apparent in non-tumor cells
such as the human breast epithelial line MCF10A (Figure S1E)
and also in mouse embryonic fibroblasts (MEFs) (Figures S1F–
S1H). To further validate our observations, we exploited small-
molecule inhibitors of POLB and POLG. Although potent or
highly specific inhibitors of POLG and POLB do not currently
exist, menadione is known to inhibit POLG (Sasaki et al.,
2008), and masticadienonic acid inhibits POLB (Boudsocq
et al., 2005). These compounds were able to elicit either MLH1
or MSH2 selectivity (Figures S1I and S1J), supporting the obser-
vations made using RNA interference.
MLH1 Deficiency Is Associated with Elevated POLG
Expression Levels and MSH2 Deficiency Is Associated
with Elevated POLB Expression
To further investigate the MSH2/POLB and MLH1/POLG SSLs,
we measured POLB and POLG mRNA levels in cells with either
MSH2 or MLH1 deficiencies. POLB mRNA levels were signifi-
cantly higher (p = 0.025) in the MSH2-deficient HEC59 cell line
than in the MSH2-proficient HEC59+Chr2 cell line (Figure 2A).
Similarly, POLG mRNA levels in the MLH1-deficient HCT116
cells were significantly higher (p = 0.0127) than in HCT116+Chr3
cells (Figure 2B). The MSH2 or MLH1 specificity of these effects
was suggested by the absence of POLG mRNA upregulation inFigure 2. MSH2 and MLH1 Deficiencies Are Associated with Particular
(A) POLB mRNA levels were analyzed by qRT-PCR using GAPDH expression a
(Student’s t test).
(B) POLG mRNA levels were analyzed by qRT-PCR using GAPDH expression as
(Student’s t test).
(C) Cell lysates fromHEC59 and HEC59+Chr2 cells were analyzed by western blot
(D) Cell lysates from HCT116 and HCT116+Chr3 cells were analyzed by wester
shown.
(E and F) Polymerase mRNA expression in MSH2- and MLH1-deficient tumors an
PCR. MSH2-deficient tumors are shown in (E) and MLH1-deficient tumors are s
having tumors with both MSH2 and MLH1 deficiency (labeled by *). MSH2 and
The relative polymerase mRNA levels were measured using qRT-PCR and norm
(E) POLB expression was elevated in MSH2-deficient tumors, compared to patie
(F) POLG expression was elevated in MLH1-deficient tumors, compared to patie
Error bars for each individual experiment represent standard errors of the mean.MSH2-deficient cells and an absence of POLB upregulation in
MLH1-deficient cells (Figures 2A and 2B). Corresponding
changes in POLB and POLG protein levels were observed in
HEC59 and HCT116 cells, respectively (Figures 2C and 2D), as
well as in additional isogenic models of MSH2 or MLH1 defi-
ciency (Figures S2A–S2C; Table S3). An increase in Msh2
expression was also observed in Polb/MEFs when compared
with their wild-type counterparts (Figure S2C).
To assess whether these alterations in POLB and POLG
expression occurred in human tumors, we measured POLB
and POLGmRNA levels in MSH2- or MLH1-deficient (as defined
by immunohistochemistry; IHC) colorectal tumor biopsies and
corresponding adjacent normal tissues. POLB mRNA levels
were consistently elevated in MSH2-negative tumors compared
with those in patient-matched MSH2-positive normal tissue
(p = 0.0096) (Figure 2E). The specificity of this observation was
suggested by an absence of POLG mRNA elevation in the
MSH2-negative tumors (Figure 2E). Similarly, MLH1-negative
tumors exhibited elevated levels of POLG expression
(p = 0.027), whereas POLB mRNA was not consistently altered
(Figure 2F). In two tumor/normal matched biopsy pairs where
the tumors were deficient of both MSH2 and MLH1, both
POLB and POLG mRNAs were elevated in the tumors (Figures
2E and 2F). These results support the conclusion that POLB
expression is elevated in MSH2-deficient tumors and POLG
expression is increased in MLH1-deficient tumors.
It has previously been suggested that SSL interactions
between genes, proteins, and indeed pathways may be as
a consequence of functional compensation or ‘‘buffering’’ (Kae-
lin, 2005). In an SSL interaction, one genemay buffer the effect of
changes in a second gene but this buffering is lost when the
function of both genes is absent (Kaelin, 2005 and references
therein). It is possible, therefore, that the increases in POLB or
POLG expression in MSH2- or MLH1-deficient cells and tumors
reflect such a buffering process.
Increased 8-OxoG Accumulation Correlates with SSL
in Both MLH1- and MSH2-Deficient Cells
Given the selectivity of POLB or POLG inhibition for either MSH2
orMLH1 deficiencies and the changes in POLB or POLG expres-
sion in MSH2- andMLH1-deficient cells, we considered whether
these observations could be explained by failure to repair
a particular DNA lesion. We investigated whether the accu-
mulation of 8-oxoG correlated with the MSH2/POLB andIncreases in DNA Polymerase Expression
s a control. *p = 0.0254 compared to the MSH2-proficient HEC59+Chr2 cells
a control. *p = 0.0127 compared to the MLH1-proficient HCT116+Chr3 cells
ting usingMSH2-, POLB-, POLG-, and b-tubulin-specific antibodies as shown.
n blotting using MLH1-, POLG-, POLB-, and b-tubulin-specific antibodies as
d adjacent nontumor material from the same patient was determined by qRT-
hown in (F). Patient samples are labeled alphabetically, with patients e and g
MLH1 protein expression was determined by immunohistochemical analysis.
alized to a housekeeping gene, GAPDH.
nt-matched nontumor material; p = 0.0096 (pairwise Student’s t test).
nt-matched nontumor material; p = 0.027 (pairwise Student’s t test).
See also Figure S2.
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8-oxoG levels from DNA extracted from total cell lysates.
Seventy-two hours after siRNA transfection, POLB silencing
caused a significant increase in 8-oxoG levels in MSH2-deficient
HEC59 cells when compared with MSH2-proficient cells (Fig-
ure 3A). POLG silencing in MLH1-deficient HCT116 cells
also resulted in an increase in 8-oxoG lesions (Figure 3B). These
effects were reminiscent of 8-oxoG increases in Msh2/;
Ogg1/ MEFs (Colussi et al., 2002), and we were able to
demonstrate that silencing of OGG1 by siRNA caused elevation
of 8-oxoG lesions in cells deficient in MSH2 or MLH1 as well as
synthetic lethality between OGG1 and MSH2 and also OGG1
and MLH1 (Figures S3A–S3C). Silencing of other DNA polymer-
ases in MLH1- or MSH2-deficient cells did not elicit the same
increases in 8-oxoG levels (Figure S3D), suggesting that these
effects were specific to POLB or POLG.
We extended our observations by examining the time course
of 8-oxoG formation. Silencing of POLB caused an initial
increase in 8-oxoG levels in both MSH2-deficient and -proficient
cells (Figure 3C). However, 48 hr after POLB siRNA transfection,
8-oxoG levels started to decrease in MSH2-proficient cells but
continued to rise in MSH2-deficient cells (Figure 3C). POLG
inhibition caused a very similar effect in MLH1-deficient cells
(Figure 3D). These observations suggested that inhibition of
specific DNA polymerases initially leads to the formation of
8-oxoG lesions that are eventually repaired in cells proficient in
MLH1 or MSH2, whereas these lesions accumulate in MLH1-
or MSH2-deficient cells. In these latter cells, it seems possible
that the level of 8-oxoG eventually reaches a threshold that
is incompatible with either cell viability or the ability to divide/
proliferate.
POLB has been implicated as an important nuclear DNA poly-
merase, whereas POLG is believed to be the only DNA poly-
merase active in mitochondria (Loeb and Monnat, 2008). In light
of this, we hypothesized that the difference in MSH2/POLB and
MLH1/POLG SSLs might be explained by 8-oxoG accumulation
in either the nucleus or mitochondria. To address this, we trans-
fected MSH2- or MLH1-proficient and -deficient cells with
control, POLB, or POLG siRNA as detailed above. However,
instead of isolating and analyzing total DNA, we fractionated
cells into mitochondrial and nuclear compartments, and then
extracted DNA and measured 8-oxoG levels by ELISA (FiguresFigure 3. Increased 8-OxoG Accumulation Correlates with Polymerase
(A) HEC59 andHEC59+Chr2 cells were transfected with siRNA. Seventy-two hour
mulation using an ELISA assay. Oxidized lesions were quantified according to a
formed in triplicate. *p% 0.0101 compared to the similarly transfected MSH2-pr
(B) HCT116 and HCT116+Chr3 cells were transfected with siRNA and analyzed
HCT116+Chr3 cells (Student’s t test).
(C) HEC59 and HEC59+Chr2 cells were transfected with siRNA and DNA and an
(D) HCT116 and HCT116+Chr3 cells were transfected with siRNA and DNA and a
(E) HCT116 andHCT116+Chr3 cells were transfected with siRNA. Nuclear andmit
mulation as in (B). Assays were performed in triplicate.
(F) HEC59 and HEC59+Chr2 cells were transfected with siRNA. Nuclear and mito
mulation as in (A). Assays were performed in triplicate.
(G) Validation of nuclear and mitochondrial fractionation. Cells were transfected
blotting. PCNA- and cytochrome c-specific antibodies were used to determine n
(H) Silencing of Mlh1 is synthetically lethal with loss of a mitochondrial isoform o
isoform of Ogg1. Fibroblasts expressing either a nuclear isoform of Ogg1, a mito
nontargeting control siRNA, Msh2 siRNA, or Mlh1 siRNA. After 5 days, cell survi
Error bars for each individual experiment represent standard errors of the mean.3E–3G). Increased 8-oxoG accumulation was observed in the
mitochondrial DNA fraction from the MLH1-deficient cells trans-
fectedwithPOLG siRNA, whereas no significant accumulation of
this lesion was observed in the nuclear DNA fraction (Figure 3E).
POLB silencing in MLH1-deficient cells did not, however,
increase nuclear or mitochondrial 8-oxoG levels (Figure 3E).
In contrast, mitochondrial and nuclear DNA extracts isolated
from MSH2-deficient cells transfected with POLG siRNA
showed no increase in 8-oxoG accumulation (Figure 3F). How-
ever, nuclear DNA from MSH2-deficient cells transfected with
POLB siRNA demonstrated a significant increase in 8-oxoG,
whereas no increase was observed in the DNA isolated from
mitochondria (Figure 3F). These observations were further vali-
dated in additional cellular models (Figures S3E and S3F).
Repair of 8-oxoG lesions by BER is initiated by removal of the
oxidized base by the DNA glycosylase OGG1. As shown above
(Figures S3A–S3C), silencing of OGG1 caused elevation of
8-oxoG lesions in cells deficient in MSH2 or MLH1. We there-
fore examined the nuclear/mitochondrial dichotomy in MEFs
expressing (1) only a nuclear isoform of human OGG1
(Nu-hOGG1), (2) a mitochondrial isoform of hOGG1 (Mt-OGG1),
or (3) no OGG1 at all (OGG1 null) (Oka et al., 2008). Silencing of
MLH1 caused a loss of viability in OGG1 null cells that was
rescued by OGG1 expression in the mitochondria but not by
OGG1 expression in the nucleus (Figure 3H). Conversely,
silencing of MSH2 caused loss of viability in OGG1 null cells
that was rescued in cells expressing the nuclear isoform of
OGG1 but not by cells expressing only a mitochondrial isoform
of OGG1 (Figure 3H). Taken together, these observations sug-
gested that in MEFs, the SSL interaction between MSH2 and
OGG1 was most likely mediated by loss of a nuclear OGG1
activity and that the MLH1/OGG1 SSL effect was mediated
by loss of a mitochondrial OGG1 activity. It is possible that
the MSH2/OGG1 and MLH1/OGG1 SSLs observed in human
tumor cells (Figure S3A) could also be explained by a similar
mechanism.
Supporting the hypothesis that the MLH1/POLG SSL effect
could be due to a mitochondrial dysfunction, we also demon-
strated that MLH1 expression was present in both the mitochon-
dria and the nucleus of human tumor cells, whereas MSH2
expression was restricted to the nucleus (Figure S3G). This latter
observation was also supported by a previous analysis of theInhibition and MSH2 or MLH1 Deficiency
s after transfection, DNAwas isolated from cells and analyzed for 8-oxoG accu-
standard curve generated using known amounts of 8-oxoG. Assays were per-
oficient HEC59+Chr2 cells (Student’s t test).
as in (A). *p % 0.002 compared to the similarly transfected MLH1-proficient
alyzed as in (A) over a 96 hr time course. Assays were performed in triplicate.
nalyzed as in (B) over a 96 hr time course. Assays were performed in triplicate.
ochondrial DNA isolated from transfected cells were analyzed for 8-oxoG accu-
chondrial DNA isolated from transfected cells were analyzed for 8-oxoG accu-
with siRNA, and nuclear and mitochondrial lysates were analyzed by western
uclear and mitochondrial fractionations, respectively.
f Ogg1, whereas silencing of Msh2 is synthetically lethal with loss of a nuclear
chondrial isoform of Ogg1, or both Ogg1 isoforms were transfected with either
val was estimated using CellTiter-Glo reagent.
See also Figure S3.
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Figure 4. MLH1/POLG and MSH2/POLB SSL Phenotypes Are Rescued by MUTYH Silencing
(A) HEC59 and HEC59+Chr2 cells were transfected with either control, POLB,MUTYH siRNA, or with siRNAs in combination, and clonogenic assays were per-
formed.
(B) HCT116 and HCT116+Chr3 cells were transfected with either control, POLB, MUTYH siRNA, or with siRNAs in combination, and clonogenic assays were
performed.
(C) HEC59 and HEC59+Chr2 cells were transfected with either control or POLB siRNA. Seventy-two hours after transfection, g-H2AX foci were quantified by
immunofluorescence. Nuclei are shown in blue and g-H2AX foci are in green. The scale bars represent 10 mm.
Error bars for each individual experiment represent standard errors of the mean. See also Figure S4.
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as a mitochondrial protein (Mootha et al., 2003). Similarly, anal-
ysis of the amino acid sequences of MSH2 and MLH1 using
the MitoProt algorithm that predicts the presence or absence
of mitochondrial target sequences (Claros and Vincens, 1996)
also suggested that MLH1 was localized to the mitochondria
(MLH1 P[0lg] score = 0.9188, MSH2 P[0lg] = 0.0166, where
P[0lg] > 0.5 indicates a predicted mitochondrial localization;
the known mitochondrial protein, POLG, has a P[0lg] = 0.8941).242 Cancer Cell 17, 235–248, March 16, 2010 ª2010 Elsevier Inc.MLH1/POLG and MSH2/POLB SSLs Are Rescued
by MUTYH Silencing
As cell death caused by an accumulation of 8-oxoG lesions
requires MUTYH activity (Oka et al., 2008), we investigated
whether the MLH1/POLG and MSH2/POLB SSLs were also
MUTYH dependent. Silencing of MUTYH rescued both MSH2/
POLB and MLH1/POLG SSLs (Figures 4A and 4B; Figure S4A),
suggesting dependency upon MUTYH and the possibility that
the formation of DSBs could explain the MSH2/POLB and
Figure 5. Depletion of Mt-CO1 DNA upon Inhibition of
POLG in MLH1-Deficient Cells
(A) HCT116 and HCT116+Chr3 cells were transfected with either
control,POLB, orPOLG siRNA.Mt-CO1DNA levels were analyzed
by qPCR with GAPDH used as a control.
(B) HEC59 and HEC59+Chr2 cells were transfected with either
control,POLB, orPOLG siRNA.Mt-CO1DNA levels were analyzed
by qPCR with GAPDH used as a control.
Error bars for each individual experiment represent standard
errors of the mean.
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efficiently monitored by the detection of nuclear g-H2AX foci
(Bonner et al., 2008). Silencing of POLB elicited an elevation in
g-H2AX foci in MSH2-deficient cells, suggesting an increase in
DSB formation (Figure 4C; Figure S4B). To assess the integrity
of mitochondrial DNA, we used quantitative PCR to measure
relative levels of a gene located in mitochondrial DNA, COX1
(aka MT-CO1) (Oka et al., 2008). Silencing of POLG caused
a significant depletion of COX1 DNA in MLH1-deficient cells
when compared with MLH1-proficient cells (Figures 5A and
5B), suggesting that the integrity of mitochondrial DNA was
compromised in MLH1/POLG-deficient cells, perhaps contrib-
uting to the MLH1/POLG SSL.OGG1 Expression Is Decreased in the Absence of POLB
Expression
We demonstrated that POLB silencing caused an increase in
8-oxoG levels in MSH2-deficient cells (Figure 3A). The role of
POLB in the repair of 8-oxoG lesions is well established and is
considered to act downstream of OGG1 (Boiteux and Radicella,
2000). Therefore, it was initially not clear why POLB silencing
would cause an increase in 8-oxoG lesions.
Like many other protein networks, components of the BER
pathway are coregulated, most likely as ameans to closely coor-
dinate pathway activity. For example, expression of the BER
scaffold protein XRCC1 determines the stability of other BER
proteins including POLB (Parsons et al., 2008). Similarly, POL k
deficiency causes an increase in the persistence of UV photo-
dimers in DNA, presumably by modulating the activity and/or
stability of upstream DNA repair proteins (Ogi and Lehmann,
2006). On this basis, we reasoned that a decrease in POLB
expression could modulate OGG1 expression and by this mech-
anism cause an increase in nuclear 8-oxoG levels in MSH2-defi-
cient cells.
POLB silencing did indeed cause a reduction in OGG1 protein
levels (Figure 6A; Figure S5A), an effect that appeared specific to
OGG1; the levels of the other BER proteins that we examined
were not ostensibly changed (Figure S5B). Furthermore, with
the exception of APE1 silencing, the inhibition of other BER
proteins did not elicit SSL with either MSH2 or MLH1 deficiency
(Figures S5C and S5D). We also observed a decrease in Ogg1
expression in Polb/ MEFs when compared with wild-type
MEFs (Figure S5E). We next investigated whether the reductionin OGG1 protein levels caused by POLB silencing could actually
elicit a reduction in 8-oxoG removal, commensurate with the
effects observed in the MSH2/POLB SSL. To assess this, we
used an in vitro OGG1 activity assay. HeLa cells were trans-
fected with either a nontargeting control siRNA, OGG1 siRNA,
or siRNA targeting POLB. Protein extracts were prepared from
transfected cells and incubated with a 23 bp oligonucleotide
duplex containing one 32P-labeled strand with an 8-oxoG lesion
at the 11th base annealed to an unlabeled complementary
strand containing dC at the opposite base position to the
8-oxoG (Figure 6B). The oligonucleotide strands were then elec-
trophoresed on a denaturing gel and cleaved product was
detected by autoradiography (Figure 6B). As expected, extracts
from HeLa cells transfected with control siRNA caused cleavage
of the 8-oxoG-radiolabeled strand, resulting in a labeled 10 base
cleavage product (Figure 6C) suggestive of normal OGG1
activity. However, cells transfected with POLB siRNA exhibited
a significant decrease in OGG1-mediated cleavage of 8-oxoG
similar to that observed upon silencing of OGG1 itself (Fig-
ure 6C). This suggested that OGG1-mediated cleavage of
8-oxoG was most likely dependent on POLB expression.
Recent work has shown that BER proteins such as POLB,
ligase III, and XRCC1, when not involved in repair complexes,
are ubiquitylated by the carboxyl terminus of Hsc70-interacting
protein (CHIP) and then degraded by the proteasome (Parsons
et al., 2008). It seemed possible, therefore, that the reduction
in OGG1 levels caused by POLB silencing could also be
mediated by a similar process. To assess this, HeLa cells were
transfected with POLB siRNA alone or POLB and CHIP siRNA
together (Figure 6D). As before, POLB silencing mediated a
decrease in OGG1 levels. However, OGG1 levels in POLB-
silenced cells could be restored by silencing of CHIP (Fig-
ure 6D). Furthermore, treatment of POLB-silenced cells with
the proteasomal inhibitor MG132 restored the expression of
OGG1 (Figure 6E; Figure S5F). Taken together, these results sug-
gested that the reduction in OGG1 levels caused by a reduction
in POLB expression were mediated by CHIP ubiquitination and
proteasomal degradation of OGG1.DISCUSSION
In their 1997 review describing how genetic approaches may be
used to identify therapeutic approaches for the treatment ofCancer Cell 17, 235–248, March 16, 2010 ª2010 Elsevier Inc. 243
Figure 6. OGG1 Cleavage Activity Is Decreased
in the Absence of POLB Expression
(A) HeLa cells were transfected with siRNA, and lysates
were analyzed for OGG1 expression 72 hr later.
(B) Schematic model for in vitro OGG1 assay. Briefly,
protein was isolated from transfected cells. The DNA sub-
strate is a 23 base oligonucleotide containing 8-oxoG at
its 11th base, labeled with 32P at its 50 end, and annealed
to its complementary strand (containing dC at the oppo-
site base position to the 8-oxoG). Upon cleavage of the
substrate by the OGG1 enzyme, the oligonucleotides
were electrophoresed on a denaturing PAGE gel, followed
by autoradiography.
(C) HeLa cells were transfected with either control, POLB,
or OGG1 siRNA and incubated with an oligonucleotide
substrate containing 8-oxoG, as described above. The
oligonucleotides were electrophoresed and a 10 base
fragment (labeled cleavage product) was revealed in
addition to the original 23 base oligonucleotide. Autoradi-
ography revealed that in the absence of POLB expression,
cleavage of the 8-OHdG lesion was significantly
decreased.
(D) HeLa cells were transfected with siRNA, and cell
lysates were analyzed 72 hr later. OGG1 expression was
suppressed by POLB siRNA but rescued by combined
silencing of POLB and CHIP.
(E) Cell lysates from HeLa cells were transfected with
siRNA and, after 48 hr, cells were treated with MG132
(50 mM). Lysates were analyzed 18 hr later by western
blotting. Antibodies directed against OGG1, POLB, and
b-tubulin were used to demonstrate reduction in expres-
sion of OGG1 after transfection with POLB siRNA, which
was rescued by treatment with the proteasomal inhibitor
MG132. See also Figure S5.
Cancer Cell
Targeting MSH2 or MLH1 Deficiencycancer, Hartwell and colleagues used data from studies in
budding yeast to highlight the potential of exploiting SSL in the
treatment of cancers characterized by specific MMR gene
defects (Hartwell et al., 1997). Here we show that SSLs involving
MLH1 or MSH2 and DNA polymerases also exist in human tumor
cells and can be exploited to specifically target cells carrying
these underlying gene defects. We also investigate the charac-
teristics of these SSLs and suggest that increases in oxidized
DNA lesions may, in part at least, explain how combining such
DNA repair defects limits the viability of tumor cells. We propose
a model (Figure 7) where MSH2 gene defects, when combined
with inhibition of POLB, lead to the accumulation of oxidized
DNA base damage. Likewise, POLG inhibition, when imposed
upon cells with MLH1 deficiency, also leads to the accumulation
of oxidized DNA damage. In both scenarios, the persistent DNA
lesions that occur either cause a loss of fitness by interfering with
the normal operation of the cell or eventually cause the formation
of more lethal DNA lesions such as double-strand DNA breaks.
Although the clinical assessment of SSLs in cancer therapy is
still at an early stage, the preliminary data are encouraging, with
a number of patients with BRCA mutation-associated cancer
showing favorable and sustained responses to high-potency244 Cancer Cell 17, 235–248, March 16, 2010 ª2010 Elsevier Inc.PARP inhibitors (Fong et al., 2009). Although
highly potent and selective POLB or POLG
inhibitors are not yet available for use in the
context of MSH2 or MLH1 deficiency, ourwork suggests that targeting these proteins and the pathways
they control is worthy of further investigation. How might such
inhibitors be used clinically? First, we propose that mecha-
nism-based biomarkers be used to identify patients likely to
respond favorably to therapy. In this case, DNA sequencing-
based detection ofMSH2 orMLH1mutations in blood and tumor
biopsies would be used (Hegde and Roa, 2009), alongside IHC
detection of MSH2 and MLH1 proteins in tumor samples to
confirm loss of heterozygosity (Shia, 2008). The work presented
here suggests that MSH2 andMLH1 deficiencies are associated
with increased expression of POLB and POLG, respectively,
and therefore IHC detection of these latter proteins in tumor
biopsies may also serve as a predictive biomarker. Our work
also suggests that combined MSH2/POLB or MLH1/POLG inhi-
bition is characterized by a sustained increase in the levels of
8-oxoG. Measuring 8-oxoG using an ELISA assay may therefore
provide a mechanism-based marker of drug efficacy to be used
alongside more standard measures of tumor response. Finally,
we propose that POLG or POLB inhibitors be used for a limited
time course rather than extended periods. Such a regime would
ideally maximize the antitumor response while limiting the poten-
tial for either deleterious long-term effects of DNA repair pathway
Figure 7. A Model for the Selective Effects
of DNA Polymerase Inhibition in MLH1- or
MSH2-Deficient Cells
Oxidized DNA lesions, including 8-oxoG, can be
repaired by either MSH2/MLH1-dependent pro-
cesses or BER. In wild-type cells, inhibition of
POLB or POLG leads to repair of these lesions
by MSH2/MLH1. In the absence of MSH2, POLB
is essential for 8-oxoG repair. Inhibition of POLB
in MSH2-deficient cells leads to the accumulation
of 8-oxoG in nuclear DNA. Cells harboring these
unrepaired lesions may permanently arrest or
die. These effects may be mediated by MUTYH,
which in attempting to reverse C/A transversions
opposite oxidized bases ultimately causes the
formation of single-strand DNA breaks which in
turn cause the formation of lethal double-strand
DNA breaks. In cells with MLH1 deficiency,
POLG inhibition leads to the accumulation of
8-oxoG inmitochondrial DNA. Again, this accumu-
lation either becomes incompatible with viability or
limits the cell’s replicative potential.
Cancer Cell
Targeting MSH2 or MLH1 Deficiencyinhibition or the development of drug resistance, including the
potential reversion of MSH2 or MLH1 gene defects, as has
been documented for BRCA gene defects (Edwards et al., 2008).
To realize the potential of our proposed synthetic lethality
approach, the development of highly potent and selective
POLB and POLG inhibitors is required. Although somewhat
specific POLB inhibitors have already been identified, these
are of low potency. For example, koetjapic acid (Sun et al.,
1999), pamoic acid (Hu et al., 2004), prunasin (Mizushina et al.,
1999), solanapyrone A (Mizushina et al., 2002), trans-communic
acid, mahureone A, and masticadienonic acid (Boudsocq et al.,
2005) all inhibit POLB. Of these, masticadienonic acid (IC50 of
8 mM) is the most potent POLB inhibitor identified to date. The
development of POLG inhibitors is also at a relatively early stage
of development; vitamin K3 (VK3; menadione) is known to inhibit
POLG with an IC50 in the micromolar range. Interestingly, VK3
causes impairment of mitochondrial DNA replication and repair,
and induces a significant increase in reactive oxygen species,
leading to cellular apoptosis (Sasaki et al., 2008). Lamivudine-
TP (LVD-TP), adefovir-diphosphate (ADV-DP), and tenofovir-
DP (TFV-DP), as well as zalcitabine-TP (ddCTP) and zidovu-Cancer Cell 17, 235–24dine-TP (AZT-TP), all inhibit POLG activity
in vitro, although the extent of inhibition
varies widely (Lewis et al., 1994; Maz-
zucco et al., 2008). It is also worth consid-
ering whether similar synthetic lethalities
could be achieved by targeting proteins
other than POLB or POLG. Silencing of
the DNA glycosylase OGG1 was also
able to elicit selectivity in cells with either
MLH1 or MSH2 deficiency (Figure S3A),
and it is possible that the catalytic activ-
ity of this protein may be more amenable
to pharmacological inhibition. It is also
possible that other SSL effects could be
exploited in the treatment of MMR-defec-
tive cancers. MMR-defective mouse andhuman cell lines have been reported to be sensitive to drugs
inducing interstrand crosslinks (ICLs) including CCNU (N-
[2-chloroethyl]-N0-cyclohexyl-N-nitrosourea) and MMC (mito-
mycin C) (Aquilina et al., 1998; Wu et al., 2005). The tolerance
and repair of ICLs is extremely complex and most likely involves
a number of pathways including MMR, translesion synthesis,
andhomologous recombination (Zhenget al., 2006). This interplay
of these repair pathways may suggest that MMR-deficient tumor
cell sensitivity to ICL-causingagentscouldbe increased inasyner-
gistic fashion, by inhibiting additional DNA repair pathways.
We do note that the SSL involving POLB is specific to MSH2
deficiency whereas the POLG SSL is specific to cells with
MLH1 defects, suggesting that the SSLs described here are
genotype specific rather than being associated with MMR defi-
ciency per se. Interestingly, there is also a growing body of
evidence to suggest that MLH1 and MSH2 not only have distinct
roles outside of the canonical MMR pathway but their defi-
ciencies also lead to distinct phenotypic and clinical manifesta-
tions. For example, MLH1 mutations are particularly associated
with an increased risk of colonic cancers, whereasMSH2muta-
tions have a higher incidence of extracolonic tumors (Kastrinos8, March 16, 2010 ª2010 Elsevier Inc. 245
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Targeting MSH2 or MLH1 Deficiencyet al., 2008; Palomaki et al., 2009). Similarly, differences in MLH1
and MSH2 function have been identified that suggest that
the canonical MMR pathway is perhaps but one mechanism
by which these proteins maintain the integrity of the genome.
Notably, the response to certain chemotherapies differs
between MLH1- and MSH2-deficient tumor cells (Martin et al.,
2009; Wu and Vasquez, 2008; Zhang et al., 2002), and MLH1
has been shown to regulate homologous recombination inde-
pendently of MSH2 (Siehler et al., 2009). Intriguingly, de Souza-
Pinto and colleagues report that mitochondria possess a distinct
version ofMMR that isMSH2 independent (de Souza-Pinto et al.,
2009), suggesting that noncanonical forms of MMR exist that are
perhaps worthy of additional study.
In summary, we provide the proof of principle that SSLs could
be exploited to design targeted therapeutic approaches to the
treatment of cancers characterized by specific MMR gene
defects. Clinical trials of these approaches will require the devel-
opment of suitable drug-like inhibitors.
EXPERIMENTAL PROCEDURES
Cell Culture
The human endometrial cell lines HEC59 andHEC59+Chr2were the kind gift of
Dr. T. Kunkel (National Institute of Environmental Health Sciences). The human
colon cancer cell lines HCT116 and HCT116+Chr3 were the kind gift of
Dr. A. Clark (NIEHS). The human ovarian tumor cell lines A2780cp70+chr3/
A2 and A2780cp70+chr3/E1 were a kind gift from Dr. R. Brown (ICR). Wild-
type and Polb/ mouse embryonic fibroblasts were obtained from the
American Type Culture Collection. Masticadienonic acid was a kind gift of
Dr. C. Cazaux (Institut de Pharmacologie et de Biologie Structurale) and
Dr. G. Massiot (Institut de Recherche, Pierre Fabre). Detailed methods for
cell culture are described in Supplemental Experimental Procedures.
Protein Analysis
Cell pellets were lysed in 20 mmol/L Tris (pH 8), 200 mmol/L NaCl, 1 mmol/L
EDTA, 0.5% (v/v) NP40, 10% (v/v) glycerol, and protease inhibitors. Mitochon-
drial and nuclear protein were extracted using a mitochondrial isolation kit
(ab65321; Abcam). For western blotting, lysates were electrophoresed on
Novex precast gels (Invitrogen) and immunoblotted. Antibody details are
described in Supplemental Experimental Procedures.
Use of RNA Interference to Assess Synthetic Lethality
Short-term and clonogenic assays were performed as described in Farmer
et al. (2005) and Martin et al. (2009). For 96-well plate-based cell viability
assays, HeLa, HCT116, HCT116+Chr3, HEC59, and HEC59+Chr2 cells were
transfected with individual siRNAs using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. A2780cp70+chr3/A2 and
A2780cp70+chr3/E1 cells were transfected with individual siRNAs using Lip-
ofectamine RNAi Max (Invitrogen) according to the manufacturer’s instruc-
tions. For clonogenic assays, exponentially growing cells were seeded at
various densities in six-well plates. Cells were transfected with siRNA as
before. Further experimental details and siRNA target sequences are detailed
in Supplemental Experimental Procedures.
Detection of g-H2AX Foci by Immunofluorescence
Transfected cells were seeded onto coverslips. Seventy-two hours posttrans-
fection, cells were fixed, permeabilized, and then incubated with g-H2AX anti-
body (Millipore) for 24 hr at 4C. Coverslips were stained with DAPI, mounted,
and viewed using a Leica TCS-SP2 confocal microscope. The experimental
procedure is described in full in Supplemental Experimental Procedures.
Immunohistochemical Staining
The use of human tissue for this study was reviewed and approved by the
Beaumont Hospital Ethics Committee and samples were obtained after
informed consent. Four micrometer sections were cut from formalin-fixed246 Cancer Cell 17, 235–248, March 16, 2010 ª2010 Elsevier Inc.paraffin-embedded samples for the purpose of immunohistochemistry.
A section of normal colon tissue was used as a positive control, and negative
controls were performed by replacing the antibody with Tris-buffered saline.
Further experimental details are described in Supplemental Experimental
Procedures.
Measurement of 8-OxoG
8-oxoG levels in DNAwere measured using an 8-oxoG-specific ELISAmethod
(Cell Biolabs) described in full in Supplemental Experimental Procedures.
In Vitro OGG1 Assay
OGG1 glycosylase activity was analyzed using the OGG1 assay kit (Sigma-
Aldrich). Detailed methods are described in Supplemental Experimental
Procedures.
Quantitative RT-PCR
Total RNA from cell lines was extracted using Trizol (Invitrogen) according to
the manufacturer’s instructions. Total RNA from patient biopsies was purified
from 10 mmsections using the High Pure RNAParaffin Kit (Roche Diagnostics).
Detailed methods for cDNA synthesis and quantitative RT-PCR are described
in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2009.12.046.
ACKNOWLEDGMENTS
We thank Dr. T. Kunkel, Dr. A. Clark, and Dr. R. Brown for the provision of cell
lines. We thank Dr. C. Cazaux and Dr. G. Massiot for providing masticadie-
nonic acid. We also thank Dr. M. Hewish for helpful discussions. C.J.L.,
A.A., and S.A.M. are inventors on a patent pertaining to this work and may
financially gain under the ICR rewards to investors scheme. This work was
supported by grants from Cancer Research UK and Breakthrough Breast
Cancer. We acknowledge NHS funding to the NIHR Biomedical Research
Centre.
Received: August 13, 2008
Revised: July 6, 2009
Accepted: January 20, 2010
Published: March 15, 2010
REFERENCES
Aquilina, G., Ceccotti, S., Martinelli, S., Hampson, R., and Bignami, M. (1998).
N-(2-chloroethyl)-N0-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-
defective human cells. Cancer Res. 58, 135–141.
Argueso, J.L., Smith, D., Yi, J., Waase, M., Sarin, S., and Alani, E. (2002). Anal-
ysis of conditional mutations in the Saccharomyces cerevisiae MLH1 gene in
mismatch repair and in meiotic crossing over. Genetics 160, 909–921.
Arnold, C.N., Goel, A., and Boland, C.R. (2003). Role of hMLH1 promoter
hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell
lines. Int. J. Cancer 106, 66–73.
Bettstetter, M., Dechant, S., Ruemmele, P., Grabowski, M., Keller, G., Holin-
ski-Feder, E., Hartmann, A., Hofstaedter, F., and Dietmaier, W. (2007). Distinc-
tion of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-
unstable colorectal cancer through quantification of MLH1 methylation by
real-time PCR. Clin. Cancer Res. 13, 3221–3228.
Boiteux, S., and Radicella, J.P. (2000). The human OGG1 gene: structure,
functions, and its implication in the process of carcinogenesis. Arch. Biochem.
Biophys. 377, 1–8.
Bonner, W.M., Redon, C.E., Dickey, J.S., Nakamura, A.J., Sedelnikova, O.A.,
Solier, S., and Pommier, Y. (2008). gH2AX and cancer. Nat. Rev. Cancer 8,
957–967.
Cancer Cell
Targeting MSH2 or MLH1 DeficiencyBoudsocq, F., Benaim, P., Canitrot, Y., Knibiehler, M., Ausseil, F., Capp, J.P.,
Bieth, A., Long, C., David, B., Shevelev, I., et al. (2005). Modulation of cellular
response to cisplatin by a novel inhibitor of DNA polymerase b. Mol. Pharma-
col. 67, 1485–1492.
Boyer, J.C., Umar, A., Risinger, J.I., Lipford, J.R., Kane, M., Yin, S., Barrett,
J.C., Kolodner, R.D., and Kunkel, T.A. (1995). Microsatellite instability,
mismatch repair deficiency, and genetic defects in human cancer cell lines.
Cancer Res. 55, 6063–6070.
Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E.,
Kyle, S., Meuth, M., Curtin, N.J., and Helleday, T. (2005). Specific killing of
BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Nature 434, 913–917.
Claros, M.G., and Vincens, P. (1996). Computational method to predict mito-
chondrially imported proteins and their targeting sequences. Eur. J. Biochem.
241, 779–786.
Colussi, C., Parlanti, E., Degan, P., Aquilina, G., Barnes, D., Macpherson, P.,
Karran, P., Crescenzi, M., Dogliotti, E., and Bignami, M. (2002). The mamma-
lian mismatch repair pathway removes DNA 8-oxodGMP incorporated from
the oxidized dNTP pool. Curr. Biol. 12, 912–918.
de Souza-Pinto, N.C., Mason, P.A., Hashiguchi, K., Weissman, L., Tian, J.,
Guay, D., Lebel, M., Stevnsner, T.V., Rasmussen, L.J., and Bohr, V.A.
(2009). Novel DNA mismatch-repair activity involving YB-1 in human mito-
chondria. DNA Repair (Amst.) 8, 704–719.
Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M.,
Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers,
C.L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine
kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037.
Echeverri, C.J., Beachy, P.A., Baum, B., Boutros, M., Buchholz, F., Chanda,
S.K., Downward, J., Ellenberg, J., Fraser, A.G., Hacohen, N., et al. (2006). Mini-
mizing the risk of reporting false positives in large-scale RNAi screens. Nat.
Methods 3, 777–779.
Edwards, S.L., Brough, R., Lord, C.J., Natrajan, R., Vatcheva, R., Levine, D.A.,
Boyd, J., Reis-Filho, J.S., and Ashworth, A. (2008). Resistance to therapy
caused by intragenic deletion in BRCA2. Nature 451, 1111–1115.
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson,
T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting
the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature
434, 917–921.
Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mor-
timer, P., Swaisland, H., Lau, A., O’Connor, M.J., et al. (2009). Inhibition of poly
(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl.
J. Med. 361, 123–134.
Hartwell, L.H., Szankasi, P., Roberts, C.J., Murray, A.W., and Friend, S.H.
(1997). Integrating genetic approaches into the discovery of anticancer drugs.
Science 278, 1064–1068.
Hegde, M.R., and Roa, B.B. (2009). Genetic testing for hereditary nonpolypo-
sis colorectal cancer (HNPCC). Curr. Protoc. Hum. Genet., Chapter 10, Unit
10.12.
Horton, J.K., Baker, A., Berg, B.J., Sobol, R.W., and Wilson, S.H. (2002).
Involvement of DNA polymerase b in protection against the cytotoxicity of
oxidative DNA damage. DNA Repair (Amst.) 1, 317–333.
Hu, H.Y., Horton, J.K., Gryk, M.R., Prasad, R., Naron, J.M., Sun, D.A., Hecht,
S.M., Wilson, S.H., and Mullen, G.P. (2004). Identification of small molecule
synthetic inhibitors of DNA polymerase b by NMR chemical shift mapping.
J. Biol. Chem. 279, 39736–39744.
Jacob, S., and Praz, F. (2002). DNA mismatch repair defects: role in colorectal
carcinogenesis. Biochimie 84, 27–47.
Jiricny, J. (2006). The multifaceted mismatch-repair system. Nat. Rev. Mol.
Cell Biol. 7, 335–346.
Kaelin, W.G., Jr. (2005). The concept of synthetic lethality in the context of anti-
cancer therapy. Nat. Rev. Cancer 5, 689–698.
Kamiya, H. (2003). Mutagenic potentials of damaged nucleic acids produced
by reactive oxygen/nitrogen species: approaches using synthetic oligonucle-
otides and nucleotides: survey and summary. Nucleic Acids Res. 31, 517–531.Kastrinos, F., Stoffel, E.M., Balmana, J., Steyerberg, E.W., Mercado, R., and
Syngal, S. (2008). Phenotype comparison of MLH1 and MSH2 mutation
carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in
the United States. Cancer Epidemiol. Biomarkers Prev. 17, 2044–2051.
Klungland, A., and Bjelland, S. (2007). Oxidative damage to purines in DNA:
role of mammalian Ogg1. DNA Repair (Amst.) 6, 481–488.
Koi, M., Umar, A., Chauhan, D.P., Cherian, S.P., Carethers, J.M., Kunkel, T.A.,
and Boland, C.R. (1994). Human chromosome 3 corrects mismatch repair
deficiency and microsatellite instability and reduces N-methyl-N0-nitro-N-
nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1
mutation. Cancer Res. 54, 4308–4312.
Lewis, W., Simpson, J.F., and Meyer, R.R. (1994). Cardiac mitochondrial DNA
polymerase-g is inhibited competitively and noncompetitively by phosphory-
lated zidovudine. Circ. Res. 74, 344–348.
Lewis, W., Day, B.J., Kohler, J.J., Hosseini, S.H., Chan, S.S., Green, E.C.,
Haase, C.P., Keebaugh, E.S., Long, R., Ludaway, T., et al. (2007). Decreased
mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac
targeted human mutant polymerase g. Lab. Invest. 87, 326–335.
Loeb, L.A., and Monnat, R.J., Jr. (2008). DNA polymerases and human
disease. Nat. Rev. Genet. 9, 594–604.
Luo, J., Solimini, N.L., and Elledge, S.J. (2009). Principles of cancer therapy:
oncogene and non-oncogene addiction. Cell 136, 823–837.
Macpherson, P., Barone, F., Maga, G., Mazzei, F., Karran, P., and Bignami, M.
(2005). 8-oxoguanine incorporation into DNA repeats in vitro and mismatch
recognition by MutSa. Nucleic Acids Res. 33, 5094–5105.
Martin, S.A., McCarthy, A., Barber, L.J., Burgess, D.J., Parry, S., Lord, C.J.,
and Ashworth, A. (2009). Methotrexate induces oxidative DNA damage and
is selectively lethal to tumour cells with defects in the DNA mismatch repair
gene MSH2. EMBO Mol. Med. 1, 323–337.
Mazzucco, C.E., Hamatake, R.K., Colonno, R.J., and Tenney, D.J. (2008).
Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial
toxicity or DNA polymerase g inhibition. Antimicrob. Agents Chemother. 52,
598–605.
Mizushina, Y., Takahashi, N., Ogawa, A., Tsurugaya, K., Koshino, H., Take-
mura, M., Yoshida, S., Matsukage, A., Sugawara, F., and Sakaguchi, K.
(1999). The cyanogenic glucoside, prunasin (D-mandelonitrile-b-D-glucoside),
is a novel inhibitor of DNA polymerase b. J. Biochem. 126, 430–436.
Mizushina, Y., Kamisuki, S., Kasai, N., Shimazaki, N., Takemura, M., Asahara,
H., Linn, S., Yoshida, S., Matsukage, A., Koiwai, O., et al. (2002). A plant phy-
totoxin, solanapyrone A, is an inhibitor of DNA polymerase b and l. J. Biol.
Chem. 277, 630–638.
Mootha, V.K., Bunkenborg, J., Olsen, J.V., Hjerrild, M., Wisniewski, J.R., Stahl,
E., Bolouri, M.S., Ray, H.N., Sihag, S., Kamal, M., et al. (2003). Integrated anal-
ysis of protein composition, tissue diversity, and gene regulation in mouse
mitochondria. Cell 115, 629–640.
Morrison, A., Johnson, A.L., Johnston, L.H., and Sugino, A. (1993). Pathway
correcting DNA replication errors in Saccharomyces cerevisiae. EMBO J. 12,
1467–1473.
Ogi, T., and Lehmann, A.R. (2006). The Y-family DNA polymerase k (pol k) func-
tions in mammalian nucleotide-excision repair. Nat. Cell Biol. 8, 640–642.
Oka, S., Ohno, M., Tsuchimoto, D., Sakumi, K., Furuichi, M., and Nakabeppu,
Y. (2008). Two distinct pathways of cell death triggered by oxidative damage to
nuclear and mitochondrial DNAs. EMBO J. 27, 421–432.
Palomaki, G.E., McClain, M.R., Melillo, S., Hampel, H.L., and Thibodeau, S.N.
(2009). EGAPP supplementary evidence review: DNA testing strategies aimed
at reducing morbidity and mortality from Lynch syndrome. Genet. Med. 11,
42–65.
Parsons, J.L., Tait, P.S., Finch, D., Dianova, I.I., Allinson, S.L., and Dianov, G.L.
(2008). CHIP-mediated degradation and DNA damage-dependent stabiliza-
tion regulate base excision repair proteins. Mol. Cell 29, 477–487.
Pavlov, Y.I., Nguyen, D., and Kunkel, T.A. (2001). Mutator effects of overpro-
ducing DNA polymerase h (Rad30) and its catalytically inactive variant in yeast.
Mutat. Res. 478, 129–139.Cancer Cell 17, 235–248, March 16, 2010 ª2010 Elsevier Inc. 247
Cancer Cell
Targeting MSH2 or MLH1 DeficiencyPeltomaki, P., and Vasen, H. (2004). Mutations associated with HNPCC
predisposition—update of ICG-HNPCC/INSiGHT mutation database. Dis.
Markers 20, 269–276.
Saffhill, R., and Ockey, C.H. (1985). Strand breaks arising from the repair of the
5-bromodeoxyuridine-substituted template and methyl methanesulphonate-
induced lesions can explain the formation of sister chromatid exchanges.
Chromosoma 92, 218–224.
Sasaki, R., Suzuki, Y., Yonezawa, Y., Ota, Y., Okamoto, Y., Demizu, Y., Huang,
P., Yoshida, H., Sugimura, K., and Mizushina, Y. (2008). DNA polymerase g
inhibition by vitamin K3 induces mitochondria-mediated cytotoxicity in human
cancer cells. Cancer Sci. 99, 1040–1048.
Shia, J. (2008). Immunohistochemistry versus microsatellite instability testing
for screening colorectal cancer patients at risk for hereditary nonpolyposis
colorectal cancer syndrome. Part I. The utility of immunohistochemistry.
J. Mol. Diagn. 10, 293–300.
Siehler, S.Y., Schrauder, M., Gerischer, U., Cantor, S., Marra, G., and Wies-
muller, L. (2009). Human MutL-complexes monitor homologous recombina-
tion independently of mismatch repair. DNA Repair (Amst.) 8, 242–252.
Strathdee, G., MacKean,M.J., Illand,M., andBrown, R. (1999). A role formeth-
ylation of the hMLH1 promoter in loss of hMLH1 expression and drug resis-
tance in ovarian cancer. Oncogene 18, 2335–2341.248 Cancer Cell 17, 235–248, March 16, 2010 ª2010 Elsevier Inc.Sun, D.A., Starck, S.R., Locke, E.P., and Hecht, S.M. (1999). DNA polymerase
b inhibitors from Sandoricum koetjape. J. Nat. Prod. 62, 1110–1113.
Tran, H.T., Keen, J.D., Kricker, M., Resnick, M.A., and Gordenin, D.A. (1997).
Hypermutability of homonucleotide runs in mismatch repair and DNA poly-
merase proofreading yeast mutants. Mol. Cell. Biol. 17, 2859–2865.
Umar, A., Koi, M., Risinger, J.I., Glaab, W.E., Tindall, K.R., Kolodner, R.D.,
Boland, C.R., Barrett, J.C., and Kunkel, T.A. (1997). Correction of hypermuta-
bility, N-methyl-N0-nitro-N-nitrosoguanidine resistance, and defective DNA
mismatch repair by introducing chromosome 2 into human tumor cells with
mutations in MSH2 and MSH6. Cancer Res. 57, 3949–3955.
Wu, Q., and Vasquez, K.M. (2008). Human MLH1 protein participates in
genomic damage checkpoint signaling in response to DNA interstrand cross-
links, while MSH2 functions in DNA repair. PLoS Genet. 4, e1000189.
Wu, Q., Christensen, L.A., Legerski, R.J., and Vasquez, K.M. (2005). Mismatch
repair participates in error-free processing of DNA interstrand crosslinks in
human cells. EMBO Rep. 6, 551–557.
Zhang, N., Lu, X., Zhang, X., Peterson, C.A., and Legerski, R.J. (2002). hMutSb
is required for the recognition and uncoupling of psoralen interstrand cross-
links in vitro. Mol. Cell. Biol. 22, 2388–2397.
Zheng, H., Wang, X., Legerski, R.J., Glazer, P.M., and Li, L. (2006). Repair of
DNA interstrand cross-links: interactions between homology-dependent and
homology-independent pathways. DNA Repair (Amst.) 5, 566–574.
